BPGbio Announces Oncology Drug Pipeline and Prostate Cancer Biomarker Developments at AACR

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that novel data insights from its oncology therapeutics and diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14 ? 19, 2023.

"BPGbio has continued to advance our research in both therapeutics and diagnostics through our Interrogative Biology platform," said Niven R. Narain, Ph.D, President & CEO. "We are pleased to present our data on BRG-399 at AACR, which is showing promising advancements towards pan-cancer activity. In addition, we will be presenting our prostate health panel, which is the first diagnostic panel developed using AI, that we will be launching with strategic partners around the world."

A summary of the presentations is as follows:

Poster 1
Topic: Development of a Novel Oral Microtubule Targeting Agent with Pan-Cancer Activity
Presentation Type: Poster Presentation
Abstract Number: 1663
Poster Presenter: Maria-Dorothea Nastke, Ph.D., Director Oncology
Authors: Maria-Dorothea Nastke¹, Jacob Matson¹, Andressa Mota¹, Archna Ravi¹, Alex Batrouni¹, Marcus O'Hara¹, Shiva Kazerounian¹, Arcan Guven¹, Nicole Pellegrino¹, Kashni Grover¹, Kayleigh Gray¹, Anne Diers¹, Michael A. Kiebish¹, Vivek K. Vishnudas¹, Stephane Gesta^1
1BPGbio, Framingham, MA USA*
Presentation Date/Time: Monday April 17, 2023 9:00 AM - 12:30 PM

Poster 2
Topic: Serum Filamin A is a Prognostic Biomarker for Screening Benign Prostatic Hyperplasia vs Prostate Cancer in Caucasian and African American Men
Presentation Type: Poster Presentation
Abstract Number: 2196
Poster Presenter: Nischal Mahaveer Chand, Senior Data Scientist
Authors: Nischal Mahaveer Chand¹, Poornima K. Tekumalla¹, Albert Dobi^2,3, Amina Ali^2,3, Gregory M. Miller¹, Juan J. Aristizabal-Henao¹, Elder Granger¹, Stephen J. Freedland⁴, Shiv Srivastava⁵, Jose, Arturo Rodriguez Rivera⁶, Arturo Mendoza⁷ David G. McLeod⁸, Niven R. Narain¹, Michael A. Kiebish^1
1BPGbio, Framingham, MA USA, ² Center for Prostate Disease Research, John P. Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD , ³Henry M. Jackson Foundation for the Advancement of Military Medicine Bethesda, Maryland, 20817, ⁴Center for Integrated Research in Cancer and Lifestyle, Cedar-Sinai, Los Angeles, CA, ⁵Department of Biochemistry and Molecular & Cell Biology, Georgetown University School of Medicine, Washington DC, USA, ⁶Hospital General de Occidente, Secretaria de Salud Gobierno del Estado de Jalisco, Mexico, ⁷National Autonomous University of Mexico, Mexico
Presentation Date/Time: Monday April 17, 2023 9:00 AM - 12:30 PM

BPGbio's Microtubule Targeting Agent & Pan Cancer

BPGbio has been conducting ongoing research on their molecule BRG399 for the treatment of solid tumors. BRG399, an oral experimental drug with favorable pharmacological properties for clinical testing, is a first in class anti-mitotic agent with broad-spectrum anti-cancer activity. BPGbio's scientists reported that the anti-mitotic activity of BRG399 is the result of an inhibition of microtubule polymerization.

BRG399 is leading the new oncology drug pipeline for BPGbio including those uniquely targeting E2 enzymes.

BPGbio's Benign Prostatic Hyperplasia (BPH) vs Prostate Cancer Screening Panel

BPGbio's prostate health screening panel is a blood-based test, and it provides guidance in men with BPH/LUTS (enlarged prostate) to determine their risk of detecting aggressive prostate cancer, avoiding the need for unnecessary biopsies. Additionally, the panel has demonstrated potential in preventing multiple unnecessary biopsies in high-risk men, who would have been guided by elevated PSA to receive a biopsy.

BPGbio's prostate health screening panel is entering into early commercialization phase.

About BPGbio, Inc.

BPGbio, Inc., is a leading AI-powered, human-biology-centered biopharmaceutical company headquartered in the greater Boston, Massachusetts area. With its intelligent Interrogative Biology platform and the largest clinically annotated non-governmental biobank in the world, BPGbio is reimagining how patient biology can be modeled using unbiased AI to accelerate and de-risk the process of drug discovery across oncology, neurology, and rare diseases. For BPGbio therapeutics and diagnostics pipeline, visit www.bpgbio.com